Sun Pharmaceutical Industries Ltd. is breaking into the branded biologics space in a competitive therapeutic category – plaque psoriasis – dominated by power players like AbbVie Inc., Johnson & Johnson and Novartis AG. The company announced March 21 that the US FDA approved Ilumya (tildrakizumab-asmn) - the company's first biologic - for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Ilumya Becomes Sun's New Branded Specialty Drug Pillar
FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.